世界中の市場調査レポートを販売!当社に無いレポートもお探しします。

レポートナンバー 0000041587

ドセタキセル市場の規模、シェア、動向分析レポート:セグメント予測、2025‐2030

Grand View Research Inc.

Docetaxel Market Size, Share & Trends Analysis Report, And Segment Forecasts, 2025- 2030

発刊日 2025/05

言語英語

体裁PDF/150ページ

ライセンス/価格150ページ

0000041587

Individual
Team
Enterprise

※ご請求は、お申込日のTTSレートで円換算し、消費税を加えた金額になります。
※本レポートは、英文です。PDF(電子媒体)での納品となります。
※本レポートは取り寄せとなりますので、申し込みからお届けまで、多少時間が掛かる場合がございます。

無料サンプル

  • サンプルはお問い合わせください。

レポート概要

ドセタキセルの市場規模、シェア、動向分析レポート:適応症別 (乳がん、非小細胞肺がん、ホルモン難治性前立腺がん、胃腺がん)、流通チャネル別、地域別、およびセグメント予測、2025-2030

ドセタキセルの市場規模と動向

世界のドセタキセルの市場規模は、2024年に13億2000万ドルと推定され、2025年から2030年にかけて5.75%のCAGRで成長すると予測されます。ドセタキセル業界は緩やかな成長を遂げています。

レポート詳細

目次

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Indication
1.2.2. Distribution Channel
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. GVR’s Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives

Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot

Chapter 3. Docetaxel Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
3.3.3. Pipeline Analysis
3.3.4. Patent Expiry Analysis
3.3.5. Pricing Analysis

Chapter 4. Docetaxel Market: Indication Business Analysis
4.1. Indication Market Share, 2024 & 2030
4.2. Indication Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Indication, 2018 to 2030 (USD Million)
4.4. Breast Cancer
4.4.1. Breast Cancer Market, 2018 - 2030 (USD Million)
4.5. Non-Small Cell Lung Cancer (NSCLC)
4.5.1. Non-Small Cell Lung Cancer (NSCLC) Market, 2018 - 2030 (USD Million)
4.6. Hormone Refractory Prostate Cancer
4.6.1. Hormone Refractory Prostate Cancer Market, 2018 - 2030 (USD Million)
4.7. Gastric Adenocarcinoma
4.7.1. Gastric Adenocarcinoma Market, 2018 - 2030 (USD Million)
4.8. Squamous Cell Carcinoma of the Head and Neck
4.8.1. Squamous Cell Carcinoma of the Head and Neck Market, 2018 - 2030 (USD Million)

Chapter 5. Docetaxel Market: Distribution Channel Business Analysis
5.1. Distribution Channel Market Share, 2024 & 2030
5.2. Distribution Channel Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
5.4. Hospital Pharmacies
5.4.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
5.5. Retail Pharmacies
5.5.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
5.6. Online Pharmacies
5.6.1. Online Pharmacies Market, 2018 - 2030 (USD Million)

Chapter 6. Docetaxel Market: Regional Estimates & Trend Analysis
6.1. Regional Market Share Analysis, 2024 & 2030
6.2. Regional Market Dashboard
6.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
6.4. North America
6.4.1. North America Docetaxel Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
6.4.2. U.S.
6.4.2.1. Key Country Dynamics
6.4.2.2. Target Disease Prevalence
6.4.2.3. Regulatory Framework
6.4.2.4. Reimbursement Framework
6.4.2.5. U.S. Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4.3. Canada
6.4.3.1. Key Country Dynamics
6.4.3.2. Target Disease Prevalence
6.4.3.3. Regulatory Framework
6.4.3.4. Reimbursement Framework
6.4.3.5. U.S. Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4.4. Mexico
6.4.4.1. Key Country Dynamics
6.4.4.2. Target Disease Prevalence
6.4.4.3. Regulatory Framework
6.4.4.4. Reimbursement Framework
6.4.4.5. Mexico Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5. Europe
6.5.1. Europe Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.2. UK
6.5.2.1. Key Country Dynamics
6.5.2.2. Target Disease Prevalence
6.5.2.3. Regulatory Framework
6.5.2.4. Reimbursement Framework
6.5.2.5. Uk Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.3. Germany
6.5.3.1. Key Country Dynamics
6.5.3.2. Target Disease Prevalence
6.5.3.3. Regulatory Framework
6.5.3.4. Reimbursement Framework
6.5.3.5. Germany Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.4. France
6.5.4.1. Key Country Dynamics
6.5.4.2. Target Disease Prevalence
6.5.4.3. Regulatory Framework
6.5.4.4. Reimbursement Framework
6.5.4.5. France Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.5. Italy
6.5.5.1. Key Country Dynamics
6.5.5.2. Target Disease Prevalence
6.5.5.3. Regulatory Framework
6.5.5.4. Reimbursement Framework
6.5.5.5. Italy Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.6. Spain
6.5.6.1. Key Country Dynamics
6.5.6.2. Target Disease Prevalence
6.5.6.3. Regulatory Framework
6.5.6.4. Reimbursement Framework
6.5.6.5. Spain Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.7. Denmark
6.5.7.1. Key Country Dynamics
6.5.7.2. Target Disease Prevalence
6.5.7.3. Regulatory Framework
6.5.7.4. Reimbursement Framework
6.5.7.5. Denmark Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.8. Sweden
6.5.8.1. Key Country Dynamics
6.5.8.2. Target Disease Prevalence
6.5.8.3. Regulatory Framework
6.5.8.4. Reimbursement Framework
6.5.8.5. Sweden Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.9. Norway
6.5.9.1. Key Country Dynamics
6.5.9.2. Target Disease Prevalence
6.5.9.3. Regulatory Framework
6.5.9.4. Reimbursement Framework
6.5.9.5. Norway Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6. Asia Pacific
6.6.1. Asia Pacific Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.2. Japan
6.6.2.1. Key Country Dynamics
6.6.2.2. Target Disease Prevalence
6.6.2.3. Regulatory Framework
6.6.2.4. Reimbursement Framework
6.6.2.5. Japan Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.3. China
6.6.3.1. Key Country Dynamics
6.6.3.2. Target Disease Prevalence
6.6.3.3. Regulatory Framework
6.6.3.4. Reimbursement Framework
6.6.3.5. China Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.4. India
6.6.4.1. Key Country Dynamics
6.6.4.2. Target Disease Prevalence
6.6.4.3. Regulatory Framework
6.6.4.4. Reimbursement Framework
6.6.4.5. India Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.5. Australia
6.6.5.1. Key Country Dynamics
6.6.5.2. Target Disease Prevalence
6.6.5.3. Regulatory Framework
6.6.5.4. Reimbursement Framework
6.6.5.5. Australia Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.6. South Korea
6.6.6.1. Key Country Dynamics
6.6.6.2. Target Disease Prevalence
6.6.6.3. Regulatory Framework
6.6.6.4. Reimbursement Framework
6.6.6.5. South Korea Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.7. Thailand
6.6.7.1. Key Country Dynamics
6.6.7.2. Target Disease Prevalence
6.6.7.3. Regulatory Framework
6.6.7.4. Reimbursement Framework
6.6.7.5. Thailand Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.7. Latin America
6.7.1. Latin America Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.7.2. Brazil
6.7.2.1. Key Country Dynamics
6.7.2.2. Target Disease Prevalence
6.7.2.3. Regulatory Framework
6.7.2.4. Reimbursement Framework
6.7.2.5. Japan Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.7.3. Argentina
6.7.3.1. Key Country Dynamics
6.7.3.2. Target Disease Prevalence
6.7.3.3. Regulatory Framework
6.7.3.4. Reimbursement Framework
6.7.3.5. China Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.8. Middle East and Africa
6.8.1. Middle East and Africa Docetaxel Market Estimates and Forecasts, 2017 - 2030 (USD Million)
6.8.2. South Africa
6.8.2.1. Key Country Dynamics
6.8.2.2. Target Disease Prevalence
6.8.2.3. Regulatory Framework
6.8.2.4. Reimbursement Framework
6.8.2.5. South Africa Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.8.3. Saudi Arabia
6.8.3.1. Key Country Dynamics
6.8.3.2. Target Disease Prevalence
6.8.3.3. Regulatory Framework
6.8.3.4. Reimbursement Framework
6.8.3.5. Saudi Arabia Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.8.4. UAE
6.8.4.1. Key Country Dynamics
6.8.4.2. Target Disease Prevalence
6.8.4.3. Regulatory Framework
6.8.4.4. Reimbursement Framework
6.8.4.5. UAE Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.8.5. Kuwait
6.8.5.1. Key Country Dynamics
6.8.5.2. Target Disease Prevalence
6.8.5.3. Regulatory Framework
6.8.5.4. Reimbursement Framework
6.8.5.5. Kuwait Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape
7.1. Participant Overview
7.2. Company Market Position Analysis
7.3. Company Categorization
7.4. Strategy Mapping
7.5. Company Profiles/Listing
7.5.1. Phyton Biotech LLC
7.5.1.1. Overview
7.5.1.2. Financial Performance
7.5.1.3. Product Benchmarking
7.5.1.4. Strategic Initiatives
7.5.2. Rochem International Inc
7.5.2.1. Overview
7.5.2.2. Financial Performance
7.5.2.3. Product Benchmarking
7.5.2.4. Strategic Initiatives
7.5.3. Alchem International Pvt Ltd
7.5.3.1. Overview
7.5.3.2. Financial Performance
7.5.3.3. Product Benchmarking
7.5.3.4. Strategic Initiatives
7.5.4. LGM Pharma
7.5.4.1. Overview
7.5.4.2. Financial Performance
7.5.4.3. Product Benchmarking
7.5.4.4. Strategic Initiatives
7.5.5. HRV Global Life Sciences
7.5.5.1. Overview
7.5.5.2. Financial Performance
7.5.5.3. Product Benchmarking
7.5.5.4. Strategic Initiatives
7.5.6. Tenatra Chemie
7.5.6.1. Overview
7.5.6.2. Financial Performance
7.5.6.3. Product Benchmarking
7.5.6.4. Strategic Initiatives
7.5.7. Teva Active Pharmaceutical Ingredients (TAPI)
7.5.7.1. Overview
7.5.7.2. Financial Performance
7.5.7.3. Product Benchmarking
7.5.7.4. Strategic Initiatives
7.5.8. Arch Pharmalabs
7.5.8.1. Overview
7.5.8.2. Financial Performance
7.5.8.3. Product Benchmarking
7.5.8.4. Strategic Initiatives
7.5.9. Aspen Pharmacare
7.5.9.1. Overview
7.5.9.2. Financial Performance
7.5.9.3. Product Benchmarking
7.5.9.4. Strategic Initiatives
7.5.10. ChemGenix Laboratories Pvt Ltd
7.5.10.1. Overview
7.5.10.2. Financial Performance
7.5.10.3. Product Benchmarking
7.5.10.4. Strategic Initiatives
7.5.11. Cipla Ltd
7.5.11.1. Overview
7.5.11.2. Financial Performance
7.5.11.3. Product Benchmarking
7.5.11.4. Strategic Initiatives

List of Tables
Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 Global docetaxel market, by region, 2018 - 2030 (USD Million)
Table 4 Global docetaxel market, by indication, 2018 - 2030 (USD Million)
Table 5 Global docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
Table 6 North America docetaxel market, by country, 2018 - 2030 (USD Million)
Table 7 North America docetaxel market, by indication, 2018 - 2030 (USD Million)
Table 8 North America docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
Table 9 U.S docetaxel market, by indication, 2018 - 2030 (USD Million)
Table 10 U.S docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
Table 11 Canada docetaxel market, by indication, 2018 - 2030 (USD Million)
Table 12 Canada docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
Table 13 Mexico docetaxel market, by indication, 2018 - 2030 (USD Million)
Table 14 Mexico docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
Table 15 Europe docetaxel market, by country, 2018 - 2030 (USD Million)
Table 16 Europe docetaxel market, by indication, 2018 - 2030 (USD Million)
Table 17 Europe docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
Table 18 UK docetaxel market, by indication, 2018 - 2030 (USD Million)
Table 19 UK docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
Table 20 Germany docetaxel market, by indication, 2018 - 2030 (USD Million)
Table 21 Germany docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
Table 22 France docetaxel market, by indication, 2018 - 2030 (USD Million)
Table 23 France docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
Table 24 Italy docetaxel market, by indication, 2018 - 2030 (USD Million)
Table 25 Italy docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
Table 26 Spain docetaxel market, by indication, 2018 - 2030 (USD Million)
Table 27 Spain docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
Table 28 Norway docetaxel market, by indication, 2018 - 2030 (USD Million)
Table 29 Norway docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
Table 30 Denmark docetaxel market, by indication, 2018 - 2030 (USD Million)
Table 31 Denmark docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
Table 32 Sweden docetaxel market, by indication, 2018 - 2030 (USD Million)
Table 33 Sweden docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
Table 34 Asia Pacific docetaxel market, by country, 2018 - 2030 (USD Million)
Table 35 Asia Pacific docetaxel market, by indication, 2018 - 2030 (USD Million)
Table 36 Asia Pacific docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
Table 37 Japan docetaxel market, by indication, 2018 - 2030 (USD Million)
Table 38 Japan docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
Table 39 China docetaxel market, by indication, 2018 - 2030 (USD Million)
Table 40 China docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
Table 41 India docetaxel market, by indication, 2018 - 2030 (USD Million)
Table 42 India docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
Table 43 Australia docetaxel market, by indication, 2018 - 2030 (USD Million)
Table 44 Australia docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
Table 45 South Korea docetaxel market, by indication, 2018 - 2030 (USD Million)
Table 46 South Korea docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
Table 47 Thailand docetaxel market, by indication, 2018 - 2030 (USD Million)
Table 48 Thailand docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
Table 49 Latin America docetaxel market, by country, 2018 - 2030 (USD Million)
Table 50 Latin America docetaxel market, by indication, 2018 - 2030 (USD Million)
Table 51 Latin America docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
Table 52 Brazil docetaxel market, by indication, 2018 - 2030 (USD Million)
Table 53 Brazil docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
Table 54 Argentina docetaxel market, by indication, 2018 - 2030 (USD Million)
Table 55 Argentina docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
Table 56 Middle East & Africa Docetaxel market, by country, 2018 - 2030 (USD Million)
Table 57 Middle East & Africa docetaxel market, by indication, 2018 - 2030 (USD Million)
Table 58 Middle East & Africa docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
Table 59 South Africa docetaxel market, by indication, 2018 - 2030 (USD Million)
Table 60 South Africa docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
Table 61 Saudi Arabia docetaxel market, by indication, 2018 - 2030 (USD Million)
Table 62 Saudi Arabia docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
Table 63 UAE docetaxel market, by indication, 2018 - 2030 (USD Million)
Table 64 UAE docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
Table 65 Kuwait docetaxel market, by indication, 2018 - 2030 (USD Million)
Table 66 Kuwait docetaxel market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures
Fig. 1 Docetaxel market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 Market formulation & validation
Fig. 8 Market snapshot
Fig. 9 Therapeutic approach and application outlook (USD Million)
Fig. 10 Competitive landscape
Fig. 11 Docetaxel market dynamics
Fig. 12 Docetaxel market: Porter’s five forces analysis
Fig. 13 Docetaxel market: PESTLE analysis
Fig. 14 Product market, 2018 - 2030 (USD Million)
Fig. 15 Breast Cancer market, 2018 - 2030 (USD Million)
Fig. 16 Non-Small Cell Lung Cancer (NSCLC) market, 2018 - 2030 (USD Million)
Fig. 17 Hormone Refractory Prostate Cancer market, 2018 - 2030 (USD Million)
Fig. 18 Gastric Adenocarcinoma market, 2018 - 2030 (USD Million)
Fig. 19 Squamous Cell Carcinoma of the Head and Neck market, 2018 - 2030 (USD Million)
Fig. 20 Distribution Channel market, 2018 - 2030 (USD Million)
Fig. 21 Hospital Pharmacies market, 2018 - 2030 (USD Million)
Fig. 22 Retail Pharmacies market, 2018 - 2030 (USD Million)
Fig. 23 Online Pharmacies market, 2018 - 2030 (USD Million)
Fig. 24 Docetaxel market revenue, by region
Fig. 25 Regional marketplace: Key takeaways
Fig. 26 North America docetaxel market, 2018 - 2030 (USD Million)
Fig. 27 U.S. country dynamics
Fig. 28 U.S. docetaxel market, 2018 - 2030 (USD Million)
Fig. 29 Canada country dynamics
Fig. 30 Canada docetaxel market, 2018 - 2030 (USD Million)
Fig. 31 Mexico country dynamics
Fig. 32 Mexico docetaxel market, 2018 - 2030 (USD Million)
Fig. 33 Europe docetaxel market, 2018 - 2030 (USD Million)
Fig. 34 UK country dynamics
Fig. 35 UK docetaxel market, 2018 - 2030 (USD Million)
Fig. 36 Germany country dynamics
Fig. 37 Germany docetaxel market, 2018 - 2030 (USD Million)
Fig. 38 France country dynamics
Fig. 39 France docetaxel market, 2018 - 2030 (USD Million)
Fig. 40 Italy country dynamics
Fig. 41 Italy docetaxel market, 2018 - 2030 (USD Million)
Fig. 42 Spain country dynamics
Fig. 43 Spain docetaxel market, 2018 - 2030 (USD Million)
Fig. 44 Norway country dynamics
Fig. 45 Norway docetaxel market, 2018 - 2030 (USD Million)
Fig. 46 Sweden country dynamics
Fig. 47 Sweden docetaxel market, 2018 - 2030 (USD Million)
Fig. 48 Denmark country dynamics
Fig. 49 Denmark docetaxel market, 2018 - 2030 (USD Million)
Fig. 50 Asia Pacific docetaxel market, 2018 - 2030 (USD Million)
Fig. 51 Japan country dynamics
Fig. 52 Japan docetaxel market, 2018 - 2030 (USD Million)
Fig. 53 China country dynamics
Fig. 54 China docetaxel market, 2018 - 2030 (USD Million)
Fig. 55 India country dynamics
Fig. 56 India docetaxel market, 2018 - 2030 (USD Million)
Fig. 57 Australia country dynamics
Fig. 58 Australia docetaxel market, 2018 - 2030 (USD Million)
Fig. 59 South Korea country dynamics
Fig. 60 South Korea docetaxel market, 2018 - 2030 (USD Million)
Fig. 61 Thailand country dynamics
Fig. 62 Thailand docetaxel market, 2018 - 2030 (USD Million)
Fig. 63 Latin America docetaxel market, 2018 - 2030 (USD Million)
Fig. 64 Brazil country dynamics
Fig. 65 Brazil docetaxel market, 2018 - 2030 (USD Million)
Fig. 66 Argentina country dynamics
Fig. 67 Argentina docetaxel market, 2018 - 2030 (USD Million)
Fig. 68 MEA docetaxel market, 2018 - 2030 (USD Million)
Fig. 69 South Africa country dynamics
Fig. 70 South Africa docetaxel market, 2018 - 2030 (USD Million)
Fig. 71 Saudi Arabia country dynamics
Fig. 72 Saudi Arabia docetaxel market, 2018 - 2030 (USD Million)
Fig. 73 UAE country dynamics
Fig. 74 UAE docetaxel market, 2018 - 2030 (USD Million)
Fig. 75 Kuwait country dynamics
Fig. 76 Kuwait docetaxel market, 2018 - 2030 (USD Million)
Fig. 77 Company categorization
Fig. 78 Company market position analysis
Fig. 79 Strategic framework

この商品のレポートナンバー

0000041587

TOP